Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia (Q36473047)

14 August 2017

1 reference

title

Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia (English)

1 reference

14 August 2017

0 references

Astermark J

1

1 reference

PubMed ID

16683997

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

12 Suppl 3

1 reference

14 August 2017

52-60

1 reference

The epidemiology of inhibitors in haemophilia A: a systematic review

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Recognition of coagulation factor VIII by CD4+ T cells of healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

The genetic basis of inhibitor development in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Mapping of genes that control the antibody response to human factor IX in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

Immunosuppressive effects of factor IX products: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01261.X

10.1111/J.1365-2516.2006.01261.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16683997